Skip to main content

Table 4 Results of the population subgroups according to the risk factors associated

From: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

  Population subgroup A Population subgroup B Population subgroup C
  Non-prophylaxis Palivizumab Incremental palivizumab vs non-prophylaxis. Non-prophylaxis Palivizumab Incremental palivizumab vs non-prophylaxis. Non-prophylaxis Palivizumab Incremental palivizumab vs non-prophylaxis.
Effectiveness
 QALYs 5.16 5.25 0.0889 5.18 5.26 0.0821 5.18 5.26 0.0822
Costs
 Total costs €1,589.57 €2,616.92 €1,027.34 €1,088.90 €2,252.69 €1,163.79 €1,063.23 €2,209.48 €1,146.25
 Prophylaxis costs €0.00 €1,886.78 €1,886.78 €0.00 € €1,886.78 €1,886.78 €0.00 €1,886.78 €1,886.78
 Hospital related costsa €1,105.98 € €571.02 €-534.96 €637.14 €216.39 €-420.75 €613.10 €174.31 €-438.79
 Recurrent wheezing costs €483.59 €159.11 €-324.48 €451.76 €149.52 € €-302.24 €450.13 €148.38 €-301.74
ICUR (€/QALY gained) 11,550.37 14,177.18 13,937.61
  1. QALY: Quality adjusted life years; Subgroup A: 2 major risk factors and 2 minor risk factors; Subgroup B: 2 major factors and 1 minor factor; Subgroup C: 2 major factors; Major factors included chronological age less than10 weeks at the beginning of RSV season or being born during the first 10 weeks of the season; school-age siblings or day-care attendance whereas minor factors included mother smoking during pregnancy and male gender [33]. Major factors: chronological age less than 10 weeks at the beginning of RSV season or being born during the first 10 weeks of the season; school-age siblings or day-care attendance. Minor factors: mother smoking during pregnancy and male gender
  2. aHospital related costs included emergency visit prior hospitalization cost, hospital and ICU admission costs